CervoMed Inc. (CRVO) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $23.79M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | John J. Alam |
| IPO Date | 2008-05-23 | CAGR | -3.97% |
| Employees | 15 | Website | www.cervomed.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $6.52M | P/E | -0.78 | Forward P/E | -1.74 | PEG | — |
| P/S | 13.95 | P/B | 0.21 | P/CF | -0.18 | P/FCF | -0.15 |
| Sales | $322,569 | Sales 1Y | inf% | Sales 3Y | inf% | Sales 5Y | inf% |
| EPS | $-3.28 | EPS 1Y | 24.42% | EPS 3Y | -65.33% | EPS 5Y | -81.06% |
| Sales QoQ | — | EPS QoQ | -25.58% | Sales QoQ Avg | — | EPS QoQ Avg | -0.79% |
| Gross Margin | 100% | Operating Margin | -9661.43% | Profit Margin | -9408.76% | ROCE | -123.15% |
| ROA | -117% | ROE | -156% | Altman Z Score | -4.02 | Piotroski Score | 3 |
| Current Ratio | 37.83 | Quick Ratio | 37.83 | Cash Ratio | 32.69 | Op. CF Ratio | -10.07 |
| Debt/Equity | — | Debt/Assets | — | Lt Debt/Equity | — | Lt Debt/Cap. | — |
| Intrst Cov. | — | Inventory Turnover | — | Asset Turnover | 0.01 | Receivables Turnover | — |
| Enterprise Value | $6.52M | P/E Ratio | -0.78 |
| Forward P/E | -1.74 | PEG Ratio | — |
| P/S Ratio | 13.95 | P/B Ratio | 0.21 |
| P/CF Ratio | -0.18 | P/FCF Ratio | -0.15 |
| EPS | $-3.28 | EPS Growth 1Y | 24.42% |
| EPS Growth 3Y | -65.33% | EPS Growth 5Y | -81.06% |
| Revenue Growth 1Y | inf% | Gross Margin | 1% |
| Operating Margin | -96.61% | Profit Margin | -94.09% |
| ROE | -1.56% | ROA | -1.17% |
| ROCE | -1.23% | Current Ratio | 37.83 |
| Quick Ratio | 37.83 | Cash Ratio | 32.69 |
| Debt/Equity | — | Interest Coverage | — |
| Altman Z Score | -4.02 | Piotroski Score | 3 |
CervoMed Inc. (CRVO) valuation & financials
CervoMed Inc. (CRVO) has a market capitalization of $23.79M and trades at a price-to-earnings ratio of -0.8. It operates in the Healthcare sector (Biotechnology).
CervoMed Inc.'s revenue grew +inf% over the last year.
CervoMed Inc.'s next earnings report is scheduled for November 12, 2026 after market close; analysts estimate EPS of $-0.61. Check the earnings calendar to see all companies reporting this week.
CervoMed Inc. (CRVO) — frequently asked questions
When does CervoMed Inc. (CRVO) report earnings next?
CervoMed Inc. is expected to report earnings on November 12, 2026 after market close. Analysts estimate EPS of $-0.61.
What is CervoMed Inc.'s market cap?
CervoMed Inc. (CRVO) has a market capitalization of $23.79M.
What is CRVO's P/E ratio?
CervoMed Inc. trades at a price-to-earnings ratio of -0.8, with trailing twelve-month EPS of $-3.28.
How fast is CervoMed Inc. growing?
CervoMed Inc.'s revenue grew +inf% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)